- Home
- RVPHW vs FRSX Comparison
RVPHW vs FRSX Comparison
Compare RVPHW & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- FRSX
- Stock Information
- Founded
- RVPHW N/A
- FRSX N/A
- Country
- RVPHW United States
- FRSX Israel
- Employees
- RVPHW 15
- FRSX N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- FRSX Computer Software: Prepackaged Software
- Sector
- RVPHW Health Care
- FRSX Technology
- Exchange
- RVPHW Nasdaq
- FRSX Nasdaq
- Market Cap
- RVPHW N/A
- FRSX N/A
- IPO Year
- RVPHW 2018
- FRSX 2017
- Fundamental
- Price
- RVPHW $0.14
- FRSX $1.22
- Analyst Decision
- RVPHW
- FRSX
- Analyst Count
- RVPHW 0
- FRSX 0
- Target Price
- RVPHW N/A
- FRSX N/A
- AVG Volume (30 Days)
- RVPHW N/A
- FRSX 1.0M
- Earning Date
- RVPHW N/A
- FRSX 11-29-2024
- Dividend Yield
- RVPHW N/A
- FRSX N/A
- EPS Growth
- RVPHW N/A
- FRSX N/A
- EPS
- RVPHW N/A
- FRSX N/A
- Revenue
- RVPHW N/A
- FRSX $473,000.00
- Revenue This Year
- RVPHW N/A
- FRSX N/A
- Revenue Next Year
- RVPHW N/A
- FRSX N/A
- P/E Ratio
- RVPHW N/A
- FRSX N/A
- Revenue Growth
- RVPHW N/A
- FRSX 3.28
- 52 Week Low
- RVPHW N/A
- FRSX $0.57
- 52 Week High
- RVPHW N/A
- FRSX $1.64
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- FRSX 81.71
- Support Level
- RVPHW N/A
- FRSX $0.61
- Resistance Level
- RVPHW N/A
- FRSX $1.28
- Average True Range (ATR)
- RVPHW 0.00
- FRSX 0.10
- MACD
- RVPHW 0.00
- FRSX 0.04
- Stochastic Oscillator
- RVPHW 0.00
- FRSX 57.30
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.